Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1550-7416

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics ; volume:23 ; number:2 ; day:7 ; month:3 ; year:2021 ; pages:1-11 ; date:3.2021
The AAPS journal / American Association of Pharmaceutical Scientists ; 23, Heft 2 (7.3.2021), 1-11, 3.2021

Creator: Twomey, Julianne D.
Zhang, Baolin

Contributor: SpringerLink (Online service)

DOI: 10.1208/s12248-021-00574-0

URN: urn:nbn:de:101:1-2021052820252357273483

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:53 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Twomey, Julianne D.
Zhang, Baolin
SpringerLink (Online service)

Other Objects (12)

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

The First FDA-Approved Antibody-Drug Conjugate

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Hochschulschrift

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Synthesis of the First FDA-Approved HIV Protease Inhibitor

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

The First FDA-Approved Antibody-Drug Conjugate

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Hochschulschrift

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Synthesis of the First FDA-Approved HIV Protease Inhibitor

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

The First FDA-Approved Antibody-Drug Conjugate

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Hochschulschrift

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Synthesis of the First FDA-Approved HIV Protease Inhibitor

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

The First FDA-Approved Antibody-Drug Conjugate

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Synthesis of the First FDA-Approved HIV Protease Inhibitor

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

The First FDA-Approved Antibody-Drug Conjugate

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Synthesis of the First FDA-Approved HIV Protease Inhibitor

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

The First FDA-Approved Antibody-Drug Conjugate

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Synthesis of the First FDA-Approved HIV Protease Inhibitor

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Related objects

Reset password